{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': '700 Saginaw Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 24.64,
 'askSize': 1000,
 'averageDailyVolume10Day': 224762,
 'averageVolume': 252195,
 'averageVolume10days': 224762,
 'beta': None,
 'beta3Year': None,
 'bid': 24.6,
 'bidSize': 1200,
 'bookValue': -42.232,
 'category': None,
 'circulatingSupply': None,
 'city': 'Redwood City',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 25.66,
 'dayLow': 24.12,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -18.434,
 'enterpriseToRevenue': 23.763,
 'enterpriseValue': 1150630912,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 31.147429,
 'fiftyTwoWeekHigh': 47.14,
 'fiftyTwoWeekLow': 17.345,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 36778065,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 100,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.01936,
 'heldPercentInstitutions': 0.47858003,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/revmed.com',
 'longBusinessSummary': 'Revolution Medicines, Inc., a clinical-stage '
                        'precision oncology company, focuses on developing '
                        'therapies to inhibit targets primarily within the RAS '
                        "and mTOR signaling pathways. The company's principal "
                        'product candidate is RMC-4630, an inhibitor of SHP2, '
                        'which is in Phase 1b/2 study for the treatment of '
                        'RAS-dependent tumors. Its products in preclinical '
                        'stage include mutant RAS proteins; SOS1, a protein '
                        'that converts RAS (OFF) to RAS (ON) in cells; and '
                        'RMC-5552, a mTORC1 inhibitor. Revolution Medicines, '
                        'Inc. has a collaboration agreement with Sanofi for '
                        'the research and development of SHP2 inhibitors. The '
                        'company was founded in 2014 and is headquartered in '
                        'Redwood City, California.',
 'longName': 'Revolution Medicines, Inc.',
 'market': 'us_market',
 'marketCap': 1624777600,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_283775412',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -70833000,
 'nextFiscalYearEnd': 1640908800,
 'open': 25.66,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650-481-6801',
 'previousClose': 26,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 33.555225,
 'profitMargins': -1.17825,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 25.66,
 'regularMarketDayLow': 24.12,
 'regularMarketOpen': 25.66,
 'regularMarketPreviousClose': 26,
 'regularMarketPrice': 25.66,
 'regularMarketVolume': 179412,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 59013900,
 'sharesPercentSharesOut': 0.027,
 'sharesShort': 1593368,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1730067,
 'shortName': 'Revolution Medicines, Inc.',
 'shortPercentOfFloat': 0.063200004,
 'shortRatio': 8,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'RVMD',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -21.247,
 'twoHundredDayAverage': 29.677876,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '2cb08d82-911b-38e3-94c5-2f2b3c1d7099',
 'volume': 179412,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.revmed.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94063'}